Greenburgh-based Regeneron Pharmaceuticals Inc. announced sales of its injectable drug for eye diseases, Eylea, rose 39 percent in the fourth quarter of 2014, to $815 million, as part of a Securities and Exchange Commission filing announcing earnings.
“In 2015, Regeneron continues on our mission to evolve into a company with multiple, commercially-important therapies for patients,” said Dr. Leonard S. Schleifer, Regeneron president and CEO, in the SEC filing. “We look forward to another strong year of Eylea growth, driven by expanded use in diabetic macular edema, as well as the potential regulatory approval and U.S. launch of Praluent for hypercholesterolemia. Regeneron also continues to advance our innovative mid- to late-stage pipeline of antibodies for people with serious diseases including rheumatoid arthritis, atopic dermatitis, asthma, chronic pain and a life-threatening infection.”
The firm announced non-GAAP (generally accepted accounting principles) adjusted earnings of $2.79 per share for the fourth quarter and $10 per share for the whole year, reflecting an increase of 25 percent in the fourth quarter against the same period in 2013, and 22 percent for the full year against 2013.
Regeneron”™s revenue was $802 million in the fourth quarter and $2.82 billion for the full year, representing growth of 31 percent for the quarter and 34 percent for the year. Net product sales totaled $522 million in the fourth quarter and $1.75 billion for 2014, compared with $406 million in the fourth quarter and $1.43 billion for 2013.
